

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.5	78.4	(35.8-148.8)	Male	4	7.3	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.5	nc	(nc-nc)
Female	48	39.2	122.4	(90.3-162.3)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	7	5.5	126.3	(50.6-260.3)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	7	12.2	57.4	(23.0-118.2)	<u>Ovary</u>				
Female	4	8.9	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.9	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	3.2	188.8	(69.0-411.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	38	34.4	110.5	(78.2-151.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.7	nc	(nc-nc)
Male	4	6.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.5	119.8	(54.7-227.4)
Male	1	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	10	9.0	110.9	(53.1-204.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.0	nc	(nc-nc)	Male	117	145.4	80.4	(66.5-96.4)
Female	1	1.1	nc	(nc-nc)	Female	147	125.7	116.9	(98.8-137.4)
<u>Lung and Bronchus</u>									
Male	16	19.6	81.5	(46.6-132.4)					
Female	23	17.2	133.7	(84.7-200.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	23.4	55.5	(29.5-94.9)	Male	4	14.8	nc	(nc-nc)
Female	11	8.6	127.3	(63.5-227.8)	Female	11	11.3	97.0	(48.3-173.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.4	114.9	(37.0-268.1)	Male	3	4.8	nc	(nc-nc)
Female	5	3.7	135.4	(43.6-316.0)	Female	2	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	13.2	83.4	(41.6-149.2)
Female	59	89.7	65.8	(50.1-84.9)	Female	9	11.6	77.7	(35.5-147.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.8	nc	(nc-nc)	Male	11	10.6	103.7	(51.7-185.6)
<u>Colon / Rectum</u>					Female	5	5.0	99.7	(32.1-232.6)
Male	30	24.3	123.3	(83.1-176.0)	<u>Ovary</u>				
Female	25	24.2	103.1	(66.7-152.2)	Female	9	7.9	114.1	(52.1-216.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	5.8	190.9	(95.2-341.6)	Male	8	8.5	93.7	(40.4-184.7)
Female	0	1.7	nc	(nc-nc)	Female	5	9.0	55.6	(17.9-129.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	43	65.7	65.5	(47.4-88.2)
Female	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.4	nc	(nc-nc)
Male	15	13.0	115.5	(64.6-190.5)	Female	6	3.4	175.5	(64.1-382.0)
Female	9	7.4	122.3	(55.8-232.1)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
<u>Leukemia</u>					Female	11	15.9	69.4	(34.6-124.2)
Male	13	9.3	139.3	(74.1-238.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	6.9	174.2	(89.9-304.3)	Female	21	20.5	102.3	(63.3-156.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	7.9	139.3	(69.4-249.3)	Male	269	290.2	92.7	(81.9-104.5)
Female	4	2.9	nc	(nc-nc)	Female	290	308.7	93.9	(83.4-105.4)
<u>Lung and Bronchus</u>									
Male	60	40.2	149.4	(114.0-192.3)					
Female	53	44.3	119.6	(89.6-156.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.7	69.0	(25.2-150.3)	Male	6	5.8	103.6	(37.8-225.5)
Female	2	2.9	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.1	136.8	(54.8-281.8)
Female	31	38.9	79.6	(54.1-113.0)	Female	2	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	6	9.6	62.6	(22.8-136.2)	<u>Ovary</u>				
Female	6	8.6	69.5	(25.4-151.3)	Female	0	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	5	3.3	151.7	(48.9-354.0)
Female	1	0.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	32	28.3	113.2	(77.4-159.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	4	5.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	7.3	68.5	(22.1-160.0)
Male	2	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	10	9.0	110.9	(53.1-203.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.2	nc	(nc-nc)	Male	98	116.1	84.4	(68.5-102.9)
Female	1	1.0	nc	(nc-nc)	Female	97	122.4	79.3	(64.3-96.7)
<u>Lung and Bronchus</u>									
Male	7	15.7	44.7	(17.9-92.0)					
Female	11	16.2	68.0	(33.9-121.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	6	7.6	78.5	(28.7-170.8)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	23	28.5	80.7	(51.1-121.0)
Female	0	0.2	nc	(nc-nc)	Female	22	24.6	89.4	(56.0-135.3)
<u>Lung and Bronchus</u>									
Male	10	3.9	256.8	(123.0-472.4)					
Female	4	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	40.0	107.6	(77.9-144.9)	Male	26	24.8	104.9	(68.5-153.7)
Female	27	14.8	182.5	(120.2-265.5)	Female	28	19.5	143.9	(95.6-207.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.9	nc	(nc-nc)	Male	9	8.2	110.2	(50.3-209.2)
Female	4	6.3	nc	(nc-nc)	Female	3	6.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	26	22.0	118.4	(77.3-173.5)
Female	175	161.3	108.5	(93.0-125.8)	Female	24	20.0	120.0	(76.9-178.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.8	nc	(nc-nc)	Male	27	18.9	142.9	(94.1-207.8)
<u>Colon / Rectum</u>					Female	9	8.9	101.3	(46.2-192.4)
Male	37	40.4	91.6	(64.5-126.3)	<u>Ovary</u>				
Female	51	41.4	123.3	(91.8-162.1)	Female	22	13.9	158.6	(99.3-240.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.3	116.7	(60.2-203.9)	Male	27	14.8	182.0	(119.9-264.8)
Female	1	2.9	nc	(nc-nc)	Female	12	15.5	77.6	(40.1-135.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.4	nc	(nc-nc)	Male	115	128.6	89.4	(73.8-107.3)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	9.3	97.2	(44.3-184.4)
Male	27	22.6	119.5	(78.7-173.9)	Female	2	5.8	nc	(nc-nc)
Female	15	13.0	115.6	(64.7-190.7)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.8	131.6	(42.4-307.0)
Male	8	6.0	134.2	(57.8-264.4)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	11	9.0	122.2	(60.9-218.6)
<u>Leukemia</u>					Female	32	26.7	119.7	(81.8-168.9)
Male	20	15.3	130.3	(79.6-201.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	11.5	113.0	(60.1-193.3)	Female	27	37.8	71.4	(47.1-103.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	14.5	62.0	(28.3-117.8)	Male	553	508.4	108.8	(99.9-118.2)
Female	5	4.9	101.2	(32.6-236.2)	Female	606	541.0	112.0	(103.3-121.3)
<u>Lung and Bronchus</u>									
Male	90	70.4	127.8	(102.8-157.1)					
Female	95	77.8	122.0	(98.7-149.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	5	5.8	86.8	(28.0-202.5)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	18.3	65.5	(33.8-114.5)
Female	0	0.2	nc	(nc-nc)	Female	10	18.2	54.8	(26.2-100.8)
<u>Lung and Bronchus</u>									
Male	1	2.4	nc	(nc-nc)					
Female	0	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.1	130.1	(80.5-198.8)	Male	11	11.2	98.4	(49.1-176.1)
Female	4	5.8	nc	(nc-nc)	Female	11	9.1	120.3	(60.0-215.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.5	199.2	(79.8-410.5)	Male	2	3.5	nc	(nc-nc)
Female	5	3.0	168.4	(54.3-392.9)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	9.9	70.5	(28.3-145.3)
Female	74	74.4	99.5	(78.1-124.9)	Female	7	8.4	83.4	(33.4-171.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	15	8.8	171.3	(95.8-282.6)
<u>Colon / Rectum</u>					Female	5	3.8	130.9	(42.2-305.5)
Male	7	18.4	38.0	(15.2-78.3)	<u>Ovary</u>				
Female	18	17.0	105.9	(62.8-167.4)	Female	2	6.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.3	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	63	51.9	121.4	(93.3-155.4)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.0	nc	(nc-nc)
Male	14	10.5	133.2	(72.8-223.5)	Female	2	2.4	nc	(nc-nc)
Female	5	5.7	87.3	(28.1-203.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.0	nc	(nc-nc)
Male	9	2.5	356.6	(162.7-676.9)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	5	5.2	95.8	(30.9-223.5)
<u>Leukemia</u>					Female	15	15.4	97.6	(54.6-161.0)
Male	9	7.0	127.7	(58.3-242.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	4.9	243.7	(125.8-425.7)	Female	14	16.5	84.8	(46.3-142.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.2	nc	(nc-nc)	Male	226	220.0	102.7	(89.7-117.0)
Female	1	2.0	nc	(nc-nc)	Female	237	238.5	99.4	(87.1-112.9)
<u>Lung and Bronchus</u>									
Male	31	28.4	109.0	(74.1-154.7)					
Female	31	31.7	97.9	(66.5-138.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.1	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.7	133.9	(43.2-312.6)
Female	23	29.0	79.3	(50.2-118.9)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.6	nc	(nc-nc)
Male	10	6.8	147.6	(70.6-271.4)	<u>Ovary</u>				
Female	8	7.2	110.7	(47.7-218.2)	Female	2	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	22.6	84.2	(50.7-131.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	8	2.3	350.9	(151.1-691.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.6	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	6	6.7	89.2	(32.6-194.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.7	nc	(nc-nc)	Male	89	87.2	102.1	(82.0-125.6)
Female	2	0.8	nc	(nc-nc)	Female	82	96.3	85.1	(67.7-105.6)
<u>Lung and Bronchus</u>									
Male	14	11.5	121.9	(66.6-204.5)					
Female	12	12.8	93.6	(48.3-163.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	7	7.4	94.4	(37.8-194.5)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.2	111.3	(47.9-219.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	6	1.7	350.8	(128.1-763.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	27	29.0	93.0	(61.2-135.3)
Female	0	0.2	nc	(nc-nc)	Female	28	23.3	120.0	(79.7-173.4)
<u>Lung and Bronchus</u>									
Male	3	4.0	nc	(nc-nc)					
Female	4	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.2	119.6	(59.6-214.0)	Male	9	5.7	159.1	(72.6-301.9)
Female	5	3.9	128.8	(41.5-300.5)	Female	3	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	5	1.5	333.0	(107.3-777.0)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.0	100.0	(32.2-233.5)
Female	45	37.7	119.5	(87.2-159.9)	Female	3	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	5	4.1	123.1	(39.7-287.2)
<u>Colon / Rectum</u>					Female	2	2.2	nc	(nc-nc)
Male	7	9.1	76.6	(30.7-157.7)	<u>Ovary</u>				
Female	9	10.6	85.1	(38.8-161.6)	Female	3	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	27	26.6	101.4	(66.8-147.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.6	106.4	(38.9-231.6)
Male	2	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.9	nc	(nc-nc)	Female	6	8.9	67.2	(24.5-146.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	115	112.8	102.0	(84.2-122.4)
Female	1	1.2	nc	(nc-nc)	Female	134	131.7	101.7	(85.2-120.5)
<u>Lung and Bronchus</u>									
Male	14	16.0	87.8	(47.9-147.3)					
Female	23	19.7	116.8	(74.0-175.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	21.8	68.7	(38.4-113.2)	Male	10	13.7	72.8	(34.8-133.8)
Female	7	8.1	86.6	(34.7-178.4)	Female	7	10.6	66.1	(26.5-136.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.0	151.4	(55.3-329.5)	Male	5	4.5	111.9	(36.1-261.2)
Female	5	3.4	146.6	(47.3-342.2)	Female	4	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	6	12.2	49.2	(18.0-107.0)
Female	66	83.6	79.0	(61.1-100.5)	Female	7	10.8	64.7	(25.9-133.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	13	10.2	127.8	(68.0-218.6)
<u>Colon / Rectum</u>					Female	6	4.7	126.9	(46.3-276.2)
Male	25	22.1	113.1	(73.1-166.9)	<u>Ovary</u>				
Female	27	22.9	118.1	(77.8-171.8)	Female	6	7.3	81.8	(29.9-178.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.6	nc	(nc-nc)	Male	8	8.1	98.6	(42.5-194.4)
Female	3	1.6	nc	(nc-nc)	Female	9	8.5	105.3	(48.0-199.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.5	343.2	(110.6-801.0)	Male	40	67.7	59.1	(42.2-80.4)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.1	nc	(nc-nc)
Male	9	12.3	73.0	(33.3-138.5)	Female	2	3.2	nc	(nc-nc)
Female	7	6.8	102.7	(41.1-211.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.6	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	14.6	nc	(nc-nc)
Male	7	8.6	81.3	(32.6-167.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.4	77.9	(25.1-181.8)	Female	23	19.3	119.2	(75.5-178.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.8	76.9	(28.1-167.4)	Male	227	277.2	81.9	(71.6-93.3)
Female	5	2.7	187.2	(60.3-436.9)	Female	276	288.2	95.8	(84.8-107.8)
<u>Lung and Bronchus</u>									
Male	34	38.5	88.4	(61.2-123.5)					
Female	49	40.9	119.9	(88.7-158.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.5	86.8	(41.6-159.7)	Male	5	7.8	64.0	(20.6-149.4)
Female	2	3.9	nc	(nc-nc)	Female	5	6.1	82.0	(26.4-191.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
Female	45	50.8	88.5	(64.6-118.5)	Female	7	5.7	122.7	(49.2-252.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	5	6.3	79.4	(25.6-185.2)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	15	13.1	114.7	(64.1-189.2)	<u>Ovary</u>				
Female	12	11.8	101.8	(52.5-177.9)	Female	2	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.1	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	29	38.4	75.5	(50.6-108.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.8	nc	(nc-nc)
Male	7	7.5	93.7	(37.6-193.1)	Female	2	1.6	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.5	326.7	(105.3-762.3)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	6	3.4	175.1	(63.9-381.1)
<u>Leukemia</u>					Female	9	9.8	91.5	(41.8-173.7)
Male	3	4.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	3.3	nc	(nc-nc)	Female	10	11.4	87.5	(41.9-160.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	4.5	nc	(nc-nc)	Male	123	156.5	78.6	(65.3-93.8)
Female	1	1.4	nc	(nc-nc)	Female	128	161.5	79.3	(66.1-94.2)
<u>Lung and Bronchus</u>									
Male	9	20.4	44.1	(20.1-83.8)					
Female	13	21.1	61.7	(32.8-105.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.3	64.7	(23.6-140.8)	Male	5	5.8	86.7	(27.9-202.3)
Female	3	2.9	nc	(nc-nc)	Female	12	3.9	304.8	(157.3-532.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.1	176.0	(80.3-334.2)
Female	34	34.2	99.4	(68.8-138.9)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	3	9.4	nc	(nc-nc)	<u>Ovary</u>				
Female	5	8.0	62.6	(20.2-146.2)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	5	3.4	147.3	(47.5-343.7)
Female	1	0.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	30	27.1	110.6	(74.6-157.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.1	nc	(nc-nc)
Male	2	5.1	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	6	2.1	285.9	(104.4-622.2)
<u>Leukemia</u>					Female	5	5.7	87.7	(28.3-204.7)
Male	1	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	6	8.1	74.2	(27.1-161.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.1	nc	(nc-nc)	Male	94	114.8	81.9	(66.2-100.2)
Female	1	1.0	nc	(nc-nc)	Female	113	110.6	102.2	(84.2-122.9)
<u>Lung and Bronchus</u>									
Male	8	16.5	48.5	(20.9-95.6)					
Female	16	15.8	101.1	(57.7-164.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.2	83.3	(30.4-181.4)	Male	2	4.2	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	28	32.4	86.4	(57.4-124.9)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	8	2.9	273.6	(117.8-539.2)
<u>Colon / Rectum</u>					Female	0	1.9	nc	(nc-nc)
Male	6	7.0	85.7	(31.3-186.6)	<u>Ovary</u>				
Female	8	9.4	85.4	(36.8-168.2)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	19	19.5	97.5	(58.7-152.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.6	nc	(nc-nc)	Female	12	7.5	159.3	(82.2-278.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.2	nc	(nc-nc)	Male	69	84.1	82.1	(63.8-103.8)
Female	1	1.1	nc	(nc-nc)	Female	81	114.8	70.6	(56.0-87.7)
<u>Lung and Bronchus</u>									
Male	7	12.2	57.5	(23.0-118.5)					
Female	7	17.0	41.1	(16.5-84.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.2	72.8	(26.6-158.4)	Male	4	5.4	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	5	4.3	115.4	(37.2-269.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.8	104.0	(33.5-242.8)
Female	40	35.4	112.8	(80.6-153.7)	Female	6	4.3	138.5	(50.6-301.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	3.9	127.2	(41.0-296.9)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	15	8.8	170.3	(95.3-281.0)	<u>Ovary</u>				
Female	11	8.9	124.0	(61.8-221.9)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	7	3.1	229.2	(91.8-472.3)
Female	1	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	28	23.6	118.5	(78.7-171.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	9	4.9	185.3	(84.5-351.8)	Female	2	1.2	nc	(nc-nc)
Female	5	2.8	177.9	(57.3-415.1)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	12	6.5	183.4	(94.7-320.4)
Male	4	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	17	7.7	220.8	(128.6-353.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	2.9	173.8	(56.0-405.6)	Male	130	104.9	123.9	(103.6-147.2)
Female	3	1.0	nc	(nc-nc)	Female	144	116.9	123.1	(103.9-145.0)
<u>Lung and Bronchus</u>									
Male	19	14.6	129.8	(78.1-202.7)					
Female	17	16.4	103.4	(60.2-165.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.8	nc	(nc-nc)	Male	5	5.8	86.6	(27.9-202.0)
Female	5	3.0	167.2	(53.9-390.3)	Female	9	4.3	210.9	(96.3-400.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
Female	41	35.2	116.4	(83.5-158.0)	Female	10	4.1	241.7	(115.7-444.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.9	nc	(nc-nc)
Male	2	9.5	nc	(nc-nc)	<u>Ovary</u>				
Female	11	8.7	126.5	(63.1-226.4)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	24	26.7	90.0	(57.7-134.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	6	5.3	113.3	(41.4-246.7)	Female	0	1.2	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.4	208.6	(67.2-486.9)
<u>Leukemia</u>					Female	7	6.4	109.8	(44.0-226.3)
Male	4	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	6	8.0	75.1	(27.4-163.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.1	nc	(nc-nc)	Male	79	114.2	69.2	(54.8-86.2)
Female	0	1.0	nc	(nc-nc)	Female	125	115.3	108.4	(90.2-129.1)
<u>Lung and Bronchus</u>									
Male	8	15.6	51.2	(22.0-100.8)					
Female	13	16.0	81.3	(43.2-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.8	68.5	(25.0-149.1)	Male	1	5.3	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.7	149.5	(59.9-308.1)
Female	26	27.9	93.2	(60.9-136.6)	Female	2	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	2	8.5	nc	(nc-nc)	<u>Ovary</u>				
Female	5	7.3	68.1	(21.9-158.9)	Female	2	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	22	25.0	87.9	(55.1-133.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	5	4.6	108.7	(35.0-253.6)	Female	0	1.0	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	0.6	1007.6	(367.9-2193.2)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.7	106.3	(34.3-248.2)
Male	2	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	5	6.3	79.2	(25.5-184.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.9	nc	(nc-nc)	Male	70	105.6	66.3	(51.7-83.8)
Female	0	0.8	nc	(nc-nc)	Female	69	93.4	73.8	(57.5-93.5)
<u>Lung and Bronchus</u>									
Male	6	15.6	38.5	(14.0-83.7)					
Female	9	13.3	67.6	(30.8-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	12.7	71.1	(32.5-135.1)
Female	0	0.1	nc	(nc-nc)	Female	11	11.4	96.5	(48.1-172.6)
<u>Lung and Bronchus</u>									
Male	0	1.8	nc	(nc-nc)					
Female	3	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.1	129.4	(75.4-207.2)	Male	23	8.9	259.5	(164.5-389.5)
Female	6	5.4	111.9	(40.8-243.5)	Female	6	7.8	77.0	(28.1-167.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	82	64.1	128.0	(101.8-158.9)	Female	8	7.5	106.2	(45.7-209.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	6	6.8	87.6	(32.0-190.7)
<u>Colon / Rectum</u>					Female	2	3.4	nc	(nc-nc)
Male	18	14.2	126.4	(74.9-199.8)	<u>Ovary</u>				
Female	16	15.4	104.2	(59.5-169.2)	Female	6	5.4	111.9	(40.9-243.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.5	141.4	(45.6-330.1)	Male	1	5.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	53	42.9	123.5	(92.5-161.6)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.2	nc	(nc-nc)
Male	4	8.4	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
Female	5	5.0	99.9	(32.2-233.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	4.0	151.0	(55.1-328.6)
<u>Leukemia</u>					Female	13	12.1	107.1	(57.0-183.2)
Male	10	5.7	176.6	(84.6-324.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.4	nc	(nc-nc)	Female	18	14.5	123.9	(73.4-195.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.0	nc	(nc-nc)	Male	184	177.1	103.9	(89.4-120.1)
Female	0	1.8	nc	(nc-nc)	Female	214	209.5	102.1	(88.9-116.8)
<u>Lung and Bronchus</u>									
Male	17	23.6	72.1	(42.0-115.5)					
Female	31	28.7	108.1	(73.4-153.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.7	93.2	(44.6-171.5)	Male	6	7.3	82.6	(30.2-179.7)
Female	4	3.3	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.4	nc	(nc-nc)
Female	37	44.6	83.0	(58.4-114.4)	Female	3	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	11	5.8	189.3	(94.3-338.7)
<u>Colon / Rectum</u>					Female	4	2.3	nc	(nc-nc)
Male	13	11.7	111.5	(59.3-190.7)	<u>Ovary</u>				
Female	9	9.5	95.0	(43.3-180.3)	Female	4	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.0	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	31	37.4	83.0	(56.4-117.8)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	8	3.4	236.2	(101.7-465.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	6	8.7	69.3	(25.3-150.8)
Male	1	4.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.8	nc	(nc-nc)	Female	9	10.2	87.8	(40.1-166.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	137	147.7	92.7	(77.9-109.6)
Female	2	1.2	nc	(nc-nc)	Female	137	140.0	97.9	(82.2-115.7)
<u>Lung and Bronchus</u>									
Male	25	19.9	125.7	(81.3-185.6)					
Female	26	18.9	137.7	(89.9-201.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	4.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	13	13.3	97.8	(52.0-167.3)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	5	4.9	101.8	(32.8-237.5)	<u>Ovary</u>				
Female	3	2.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	16.3	36.8	(13.4-80.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	44	63.3	69.5	(50.5-93.3)
Female	0	0.4	nc	(nc-nc)	Female	43	42.2	101.8	(73.7-137.2)
<u>Lung and Bronchus</u>									
Male	10	9.0	110.6	(53.0-203.5)					
Female	9	5.8	156.2	(71.3-296.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.1	54.9	(17.7-128.1)	Male	3	6.1	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.3	130.9	(52.4-269.8)
Female	28	24.7	113.5	(75.4-164.1)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	4.8	104.0	(33.5-242.6)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	3	9.9	nc	(nc-nc)	<u>Ovary</u>				
Female	10	5.4	184.9	(88.5-340.1)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	22	31.0	70.9	(44.4-107.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.2	nc	(nc-nc)
Male	2	5.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.7	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.5	nc	(nc-nc)	Male	87	123.0	70.7	(56.7-87.3)
Female	0	0.6	nc	(nc-nc)	Female	76	76.8	99.0	(78.0-123.9)
<u>Lung and Bronchus</u>									
Male	5	16.5	30.3	(9.8-70.8)					
Female	8	10.0	80.1	(34.5-157.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	23.3	124.5	(83.4-178.9)	Male	26	13.3	194.8	(127.2-285.4)
Female	7	8.5	82.4	(33.0-169.8)	Female	17	9.8	173.8	(101.2-278.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	8	4.4	180.8	(77.9-356.3)
Female	5	3.1	158.9	(51.2-370.9)	Female	7	3.8	184.0	(73.7-379.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	18	11.7	153.3	(90.8-242.3)
Female	109	81.7	133.4	(109.5-160.9)	Female	7	10.8	64.6	(25.9-133.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	8	8.8	90.4	(38.9-178.2)
<u>Colon / Rectum</u>					Female	5	4.6	107.7	(34.7-251.3)
Male	25	21.5	116.0	(75.1-171.3)	<u>Ovary</u>				
Female	37	22.3	165.8	(116.7-228.6)	Female	4	7.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.4	111.4	(40.7-242.5)	Male	6	8.1	74.2	(27.1-161.5)
Female	0	1.6	nc	(nc-nc)	Female	8	8.8	91.2	(39.3-179.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	90	62.1	144.8	(116.5-178.0)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.1	137.3	(55.0-282.9)
Male	12	11.2	107.2	(55.3-187.3)	Female	1	3.2	nc	(nc-nc)
Female	5	6.9	72.7	(23.4-169.7)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.5	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	7	4.0	174.1	(69.8-358.8)
<u>Leukemia</u>					Female	5	11.5	43.3	(14.0-101.1)
Male	10	8.3	120.9	(57.9-222.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.1	113.9	(45.6-234.8)	Female	20	19.2	104.0	(63.5-160.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.9	86.4	(31.5-188.0)	Male	336	266.0	126.3	(113.2-140.6)
Female	3	2.7	nc	(nc-nc)	Female	327	284.5	114.9	(102.8-128.1)
<u>Lung and Bronchus</u>									
Male	44	40.1	109.6	(79.6-147.2)					
Female	46	44.8	102.7	(75.1-136.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.3	94.2	(30.4-219.9)	Male	4	3.3	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	21	18.9	111.3	(68.9-170.1)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.3	94.9	(30.6-221.5)	<u>Ovary</u>				
Female	9	4.5	200.5	(91.5-380.6)	Female	3	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	16	16.3	98.1	(56.0-159.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.2	nc	(nc-nc)
Male	6	3.0	201.9	(73.7-439.5)	Female	0	0.6	nc	(nc-nc)
Female	6	1.5	400.0	(146.1-870.7)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.2	nc	(nc-nc)	Female	5	4.3	115.4	(37.2-269.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	63	66.5	94.8	(72.8-121.2)
Female	1	0.5	nc	(nc-nc)	Female	72	61.4	117.4	(91.8-147.8)
<u>Lung and Bronchus</u>									
Male	9	9.8	92.2	(42.1-175.0)					
Female	8	9.0	88.8	(38.2-174.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	61.0	88.5	(66.5-115.5)	Male	29	39.9	72.7	(48.7-104.5)
Female	33	21.5	153.6	(105.7-215.7)	Female	17	32.2	52.8	(30.7-84.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.1	115.4	(63.0-193.6)	Male	8	12.6	63.5	(27.3-125.0)
Female	16	10.5	152.1	(86.9-247.0)	Female	10	10.2	98.2	(47.0-180.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.1	nc	(nc-nc)	Male	36	35.6	101.2	(70.9-140.2)
Female	242	255.2	94.8	(83.3-107.6)	Female	39	30.4	128.5	(91.4-175.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.8	102.1	(46.6-193.8)	Male	27	30.0	90.0	(59.3-131.0)
<u>Colon / Rectum</u>					Female	12	13.7	87.7	(45.3-153.3)
Male	64	65.9	97.2	(74.8-124.1)	<u>Ovary</u>				
Female	71	63.5	111.8	(87.3-141.0)	Female	18	22.0	81.9	(48.5-129.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	15.5	84.1	(44.7-143.8)	Male	23	22.8	101.1	(64.1-151.7)
Female	8	4.2	188.9	(81.3-372.3)	Female	28	22.5	124.2	(82.5-179.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.0	120.5	(44.0-262.3)	Male	156	183.1	85.2	(72.4-99.7)
Female	4	4.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	18	14.5	124.5	(73.7-196.8)
Male	36	35.9	100.2	(70.1-138.7)	Female	7	8.9	79.0	(31.7-162.8)
Female	23	20.1	114.4	(72.5-171.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	9.8	71.3	(28.6-146.9)
Male	12	8.9	134.4	(69.4-234.7)	<u>Thyroid</u>				
Female	5	2.8	179.0	(57.7-417.8)	Male	16	17.0	94.3	(53.9-153.2)
<u>Leukemia</u>					Female	61	50.6	120.5	(92.1-154.8)
Male	22	25.4	86.8	(54.4-131.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	18.4	119.6	(74.9-181.1)	Female	69	57.6	119.8	(93.2-151.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	22.2	72.2	(41.3-117.3)	Male	723	787.2	91.8	(85.3-98.8)
Female	6	7.4	81.6	(29.8-177.6)	Female	895	843.6	106.1	(99.2-113.3)
<u>Lung and Bronchus</u>									
Male	116	104.3	111.2	(91.9-133.4)					
Female	134	112.5	119.1	(99.8-141.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.2	65.5	(23.9-142.6)
Female	0	0.1	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	14.0	85.9	(44.4-150.1)
Female	0	0.1	nc	(nc-nc)	Female	11	11.5	95.4	(47.5-170.7)
<u>Lung and Bronchus</u>									
Male	3	1.9	nc	(nc-nc)					
Female	1	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	31.5	101.6	(69.5-143.4)	Male	34	19.1	178.4	(123.5-249.3)
Female	12	11.8	101.6	(52.4-177.5)	Female	31	14.8	208.9	(141.9-296.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.2	154.0	(66.3-303.6)	Male	7	6.1	115.5	(46.3-238.0)
Female	5	4.7	105.7	(34.1-246.7)	Female	5	5.4	92.4	(29.8-215.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	14	16.7	83.6	(45.7-140.3)
Female	108	119.5	90.4	(74.1-109.1)	Female	21	15.5	135.5	(83.8-207.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.6	nc	(nc-nc)	Male	14	13.3	105.4	(57.6-176.9)
<u>Colon / Rectum</u>					Female	6	6.8	88.8	(32.4-193.3)
Male	35	31.8	110.2	(76.7-153.2)	<u>Ovary</u>				
Female	36	33.8	106.6	(74.6-147.5)	Female	9	10.5	85.8	(39.2-163.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	7.3	nc	(nc-nc)	Male	9	11.2	80.4	(36.7-152.7)
Female	7	2.3	311.1	(124.6-640.9)	Female	14	12.6	111.4	(60.8-186.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	93	83.8	110.9	(89.5-135.9)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	7.1	168.6	(87.0-294.5)
Male	16	16.3	97.9	(55.9-159.0)	Female	1	4.7	nc	(nc-nc)
Female	7	9.8	71.5	(28.6-147.3)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.1	193.1	(70.5-420.2)
Male	2	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
<u>Leukemia</u>					Female	22	19.4	113.3	(71.0-171.6)
Male	14	12.0	116.6	(63.7-195.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	9.3	151.3	(82.6-253.9)	Female	19	26.9	70.6	(42.5-110.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	9.9	nc	(nc-nc)	Male	368	372.3	98.8	(89.0-109.5)
Female	1	3.8	nc	(nc-nc)	Female	395	412.8	95.7	(86.5-105.6)
<u>Lung and Bronchus</u>									
Male	28	52.9	52.9	(35.2-76.5)					
Female	46	59.6	77.2	(56.5-103.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	15	9.9	152.0	(85.0-250.8)	Female	2	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	8.8	113.0	(54.1-207.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	34	36.2	93.9	(65.0-131.3)
Female	0	0.3	nc	(nc-nc)	Female	41	31.9	128.6	(92.3-174.4)
<u>Lung and Bronchus</u>									
Male	5	4.8	103.6	(33.4-241.9)					
Female	6	4.4	136.5	(49.8-297.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.6	125.2	(72.9-200.5)	Male	5	8.6	57.9	(18.7-135.1)
Female	7	4.7	148.2	(59.4-305.4)	Female	1	6.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	6	2.2	275.6	(100.6-599.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	7.6	131.8	(63.1-242.3)
Female	55	54.3	101.3	(76.3-131.9)	Female	10	6.4	155.1	(74.2-285.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.7	nc	(nc-nc)	Male	6	6.2	96.8	(35.3-210.7)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	18	14.1	127.5	(75.5-201.5)	<u>Ovary</u>				
Female	19	13.3	143.3	(86.2-223.7)	Female	10	4.6	216.4	(103.6-397.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	3.3	210.4	(84.3-433.4)	Male	3	4.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	5	4.8	103.8	(33.4-242.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	41	37.8	108.4	(77.8-147.1)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.2	nc	(nc-nc)
Male	12	7.5	159.5	(82.3-278.6)	Female	1	1.9	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.6	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	9.9	60.7	(22.2-132.2)
Male	5	5.3	93.5	(30.1-218.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.6	165.1	(60.3-359.5)	Female	10	12.3	81.4	(39.0-149.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.6	129.0	(47.1-280.9)	Male	177	167.9	105.5	(90.5-122.2)
Female	1	1.6	nc	(nc-nc)	Female	195	178.8	109.0	(94.3-125.5)
<u>Lung and Bronchus</u>									
Male	20	23.5	85.0	(51.9-131.2)					
Female	32	25.7	124.4	(85.1-175.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.8	70.7	(38.6-118.7)	Male	19	12.9	147.2	(88.6-229.9)
Female	14	6.8	206.3	(112.7-346.1)	Female	13	9.9	130.8	(69.6-223.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.9	nc	(nc-nc)	Male	7	4.2	168.3	(67.4-346.9)
Female	4	3.2	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	11	11.4	96.2	(47.9-172.1)
Female	93	80.4	115.7	(93.4-141.8)	Female	8	9.6	83.6	(36.0-164.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	14	9.9	141.6	(77.3-237.6)
<u>Colon / Rectum</u>					Female	6	4.3	140.0	(51.1-304.7)
Male	18	21.2	84.8	(50.2-134.0)	<u>Ovary</u>				
Female	14	19.8	70.7	(38.6-118.6)	Female	7	6.9	101.9	(40.8-210.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.1	136.6	(54.7-281.4)	Male	12	7.5	161.0	(83.1-281.2)
Female	2	1.3	nc	(nc-nc)	Female	8	7.1	113.0	(48.7-222.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	65	61.7	105.4	(81.3-134.3)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.7	nc	(nc-nc)
Male	8	11.8	67.7	(29.1-133.3)	Female	5	2.8	179.6	(57.9-419.0)
Female	5	6.3	79.4	(25.6-185.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.6	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.3	133.1	(53.3-274.3)
<u>Leukemia</u>					Female	11	15.2	72.2	(36.0-129.3)
Male	7	8.1	86.6	(34.7-178.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.6	125.4	(50.2-258.3)	Female	32	18.2	175.5	(120.1-247.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.3	95.3	(38.2-196.4)	Male	252	257.5	97.9	(86.1-110.7)
Female	3	2.3	nc	(nc-nc)	Female	296	264.0	112.1	(99.7-125.7)
<u>Lung and Bronchus</u>									
Male	22	34.7	63.3	(39.7-95.9)					
Female	36	35.8	100.6	(70.5-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	9	10.6	84.6	(38.6-160.7)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.5	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	10.3	48.4	(15.6-113.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	0.7	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	35	41.4	84.6	(58.9-117.7)
Female	0	0.3	nc	(nc-nc)	Female	35	33.3	105.0	(73.1-146.0)
<u>Lung and Bronchus</u>									
Male	6	5.7	105.6	(38.6-229.9)					
Female	6	4.3	139.4	(50.9-303.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	14.7	150.1	(94.0-227.3)	Male	11	9.8	112.4	(56.0-201.1)
Female	2	5.1	nc	(nc-nc)	Female	12	7.7	155.7	(80.4-272.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.9	204.0	(74.5-444.1)	Male	6	3.1	191.1	(69.8-416.1)
Female	3	2.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.7	138.6	(71.5-242.0)
Female	68	64.0	106.3	(82.5-134.7)	Female	8	7.2	110.4	(47.5-217.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	6	7.8	77.3	(28.2-168.3)
<u>Colon / Rectum</u>					Female	5	3.3	149.7	(48.2-349.4)
Male	15	16.1	93.0	(52.0-153.5)	<u>Ovary</u>				
Female	14	15.1	92.7	(50.6-155.5)	Female	4	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.9	nc	(nc-nc)	Male	5	5.6	88.5	(28.5-206.5)
Female	2	1.0	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	49	49.0	100.0	(74.0-132.3)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	3.6	nc	(nc-nc)
Male	12	9.3	129.3	(66.8-225.9)	Female	1	2.1	nc	(nc-nc)
Female	5	4.9	101.7	(32.8-237.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	14	12.3	113.9	(62.2-191.2)
Male	8	6.1	131.7	(56.7-259.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.3	nc	(nc-nc)	Female	20	14.5	138.2	(84.4-213.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.6	nc	(nc-nc)	Male	203	197.3	102.9	(89.2-118.0)
Female	4	1.8	nc	(nc-nc)	Female	205	205.3	99.9	(86.7-114.5)
<u>Lung and Bronchus</u>									
Male	19	26.1	72.8	(43.8-113.7)					
Female	19	27.0	70.3	(42.3-109.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	39.2	74.0	(49.5-106.2)	Male	13	24.7	52.7	(28.0-90.1)
Female	10	15.6	64.2	(30.7-118.0)	Female	13	21.2	61.5	(32.7-105.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.6	105.6	(45.5-208.0)	Male	3	7.7	nc	(nc-nc)
Female	5	7.0	71.8	(23.1-167.6)	Female	4	7.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	17	22.1	77.0	(44.8-123.3)
Female	136	162.6	83.6	(70.2-98.9)	Female	19	20.8	91.4	(55.0-142.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.5	109.5	(40.0-238.4)	Male	21	17.4	120.7	(74.7-184.6)
<u>Colon / Rectum</u>					Female	10	9.1	110.0	(52.7-202.3)
Male	40	40.9	97.9	(69.9-133.3)	<u>Ovary</u>				
Female	43	44.9	95.8	(69.3-129.0)	Female	14	14.3	97.8	(53.4-164.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	9.3	53.9	(17.4-125.9)	Male	14	14.1	99.2	(54.2-166.5)
Female	0	3.0	nc	(nc-nc)	Female	20	16.4	121.9	(74.4-188.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.1	163.5	(52.7-381.5)	Male	96	103.6	92.6	(75.0-113.1)
Female	6	2.9	206.6	(75.4-449.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.0	88.9	(38.3-175.3)
Male	24	21.3	112.9	(72.3-168.0)	Female	9	6.3	143.0	(65.2-271.4)
Female	12	13.3	90.1	(46.5-157.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	5.8	nc	(nc-nc)
Male	9	5.3	169.7	(77.4-322.1)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	1	9.7	nc	(nc-nc)
<u>Leukemia</u>					Female	27	31.3	86.4	(56.9-125.7)
Male	10	16.3	61.3	(29.4-112.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	12.8	85.6	(42.7-153.2)	Female	42	35.6	118.0	(85.1-159.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	19	12.9	147.1	(88.5-229.8)	Male	444	478.1	92.9	(84.4-101.9)
Female	4	5.0	nc	(nc-nc)	Female	523	563.1	92.9	(85.1-101.2)
<u>Lung and Bronchus</u>									
Male	69	65.7	105.0	(81.7-132.9)					
Female	73	79.4	92.0	(72.1-115.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.2	113.4	(45.4-233.7)	Male	2	3.8	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	27	26.1	103.3	(68.1-150.4)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	7	6.7	104.9	(42.0-216.2)	<u>Ovary</u>				
Female	9	7.1	127.3	(58.1-241.6)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	22	15.7	140.0	(87.7-212.0)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.4	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.0	139.4	(55.9-287.3)
Male	1	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	7	5.6	124.6	(49.9-256.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.0	nc	(nc-nc)	Male	86	73.7	116.7	(93.4-144.2)
Female	0	0.8	nc	(nc-nc)	Female	89	88.3	100.8	(80.9-124.0)
<u>Lung and Bronchus</u>									
Male	16	9.6	166.6	(95.1-270.5)					
Female	13	11.9	109.0	(58.0-186.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.2	114.8	(62.7-192.7)	Male	9	8.8	102.0	(46.5-193.6)
Female	11	4.6	240.3	(119.8-430.0)	Female	10	7.9	126.6	(60.6-232.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.8	89.3	(35.8-183.9)
Female	67	65.1	102.9	(79.8-130.7)	Female	5	7.0	71.3	(23.0-166.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.5	nc	(nc-nc)	Male	10	7.2	138.5	(66.3-254.7)
<u>Colon / Rectum</u>					Female	2	3.2	nc	(nc-nc)
Male	18	14.6	123.1	(72.9-194.5)	<u>Ovary</u>				
Female	12	14.5	82.9	(42.8-144.8)	Female	4	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	8	4.8	168.2	(72.4-331.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	59	41.7	141.6	(107.8-182.7)
Female	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	3	8.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	1	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	9	4.4	205.6	(93.8-390.2)
<u>Leukemia</u>					Female	13	13.9	93.2	(49.6-159.4)
Male	0	5.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	4.2	nc	(nc-nc)	Female	10	14.0	71.6	(34.3-131.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.1	nc	(nc-nc)	Male	177	174.2	101.6	(87.2-117.7)
Female	0	1.6	nc	(nc-nc)	Female	188	202.0	93.1	(80.2-107.4)
<u>Lung and Bronchus</u>									
Male	14	21.9	63.8	(34.9-107.1)					
Female	23	24.6	93.7	(59.4-140.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.7	185.3	(59.7-432.5)
Female	13	18.6	70.0	(37.2-119.6)	Female	2	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	0.9	547.4	(176.4-1277.5)
Male	0	5.1	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.9	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	14.2	91.8	(48.9-157.1)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.1	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.9	129.0	(41.6-301.1)
Male	2	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.7	nc	(nc-nc)	Male	46	59.8	76.9	(56.3-102.6)
Female	0	0.5	nc	(nc-nc)	Female	61	56.7	107.6	(82.3-138.3)
<u>Lung and Bronchus</u>									
Male	6	7.8	77.0	(28.1-167.5)					
Female	9	6.9	130.9	(59.7-248.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	21.5	97.8	(60.5-149.4)	Male	13	14.0	92.9	(49.4-158.9)
Female	8	8.4	95.8	(41.2-188.7)	Female	7	11.5	60.6	(24.3-124.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.2	142.7	(52.1-310.7)	Male	4	4.5	nc	(nc-nc)
Female	5	3.7	133.4	(43.0-311.2)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	6	12.3	48.7	(17.8-105.9)
Female	96	95.9	100.1	(81.1-122.3)	Female	10	11.4	87.8	(42.0-161.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	14	10.5	132.8	(72.6-222.9)
<u>Colon / Rectum</u>					Female	6	5.1	117.4	(42.9-255.5)
Male	26	22.6	115.3	(75.3-168.9)	<u>Ovary</u>				
Female	34	23.1	147.0	(101.8-205.4)	Female	9	8.1	111.1	(50.7-211.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.6	nc	(nc-nc)	Male	3	8.1	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	4	8.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	66	69.0	95.7	(74.0-121.8)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.1	nc	(nc-nc)
Male	11	13.0	84.7	(42.2-151.5)	Female	6	3.3	183.1	(66.9-398.7)
Female	9	7.6	117.7	(53.7-223.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.0	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.1	nc	(nc-nc)	Male	7	5.8	121.4	(48.7-250.2)
<u>Leukemia</u>					Female	29	17.4	166.9	(111.8-239.8)
Male	7	8.7	80.4	(32.2-165.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.6	nc	(nc-nc)	Female	23	22.0	104.7	(66.4-157.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.7	nc	(nc-nc)	Male	256	281.3	91.0	(80.2-102.9)
Female	3	2.8	nc	(nc-nc)	Female	320	316.4	101.1	(90.4-112.8)
<u>Lung and Bronchus</u>									
Male	33	39.0	84.6	(58.2-118.8)					
Female	35	45.6	76.8	(53.5-106.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	15.3	98.1	(54.9-161.9)	Male	14	9.6	145.7	(79.6-244.6)
Female	8	5.9	136.6	(58.8-269.2)	Female	14	7.7	181.1	(98.9-303.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
Female	61	65.3	93.4	(71.5-120.0)	Female	11	7.9	138.6	(69.1-247.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	9	7.3	123.8	(56.5-235.1)
<u>Colon / Rectum</u>					Female	5	3.6	140.8	(45.4-328.6)
Male	17	15.3	110.8	(64.5-177.5)	<u>Ovary</u>				
Female	17	15.9	107.1	(62.3-171.4)	Female	5	5.6	88.9	(28.6-207.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.0	nc	(nc-nc)	Male	7	5.7	122.7	(49.1-252.8)
Female	0	1.2	nc	(nc-nc)	Female	8	6.0	134.1	(57.8-264.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	0.8	nc	(nc-nc)	Male	36	49.2	73.2	(51.3-101.4)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.6	nc	(nc-nc)
Male	13	8.7	148.7	(79.1-254.3)	Female	1	2.2	nc	(nc-nc)
Female	5	5.3	94.9	(30.6-221.5)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.3	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	0.8	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	7	10.6	65.9	(26.4-135.8)
Male	4	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.4	nc	(nc-nc)	Female	20	15.7	127.5	(77.8-196.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	5.7	194.2	(96.8-347.6)	Male	193	195.3	98.8	(85.4-113.8)
Female	0	2.0	nc	(nc-nc)	Female	225	216.4	104.0	(90.8-118.5)
<u>Lung and Bronchus</u>									
Male	21	27.8	75.5	(46.7-115.4)					
Female	36	31.9	112.7	(78.9-156.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	10	9.5	104.9	(50.2-192.9)	Female	4	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.0	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	8.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	3	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	37	32.1	115.3	(81.2-158.9)
Female	0	0.3	nc	(nc-nc)	Female	33	29.8	110.9	(76.3-155.7)
<u>Lung and Bronchus</u>									
Male	7	4.3	162.0	(64.9-333.9)					
Female	5	4.1	122.0	(39.3-284.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	17.5	114.1	(69.7-176.3)	Male	20	11.4	175.9	(107.4-271.7)
Female	10	6.8	146.6	(70.2-269.6)	Female	9	8.9	101.0	(46.1-191.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	15	10.0	149.8	(83.8-247.2)
Female	91	73.0	124.6	(100.3-153.0)	Female	11	9.2	119.6	(59.6-214.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	7	8.8	79.7	(31.9-164.2)
<u>Colon / Rectum</u>					Female	4	4.0	nc	(nc-nc)
Male	17	18.6	91.4	(53.2-146.4)	<u>Ovary</u>				
Female	15	19.3	77.6	(43.4-127.9)	Female	3	6.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	4.6	196.5	(89.7-373.1)	Male	7	6.6	105.4	(42.2-217.2)
Female	2	1.3	nc	(nc-nc)	Female	5	7.2	69.6	(22.4-162.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	62	56.7	109.3	(83.8-140.1)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.2	nc	(nc-nc)
Male	5	10.6	47.4	(15.3-110.5)	Female	5	2.7	183.3	(59.1-427.9)
Female	7	5.8	119.7	(48.0-246.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.0	247.1	(79.6-576.7)
Male	2	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Leukemia</u>					Female	15	11.9	125.6	(70.3-207.3)
Male	5	6.9	72.3	(23.3-168.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	5.2	nc	(nc-nc)	Female	15	17.0	88.4	(49.5-145.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.5	93.0	(34.0-202.5)	Male	235	229.1	102.6	(89.9-116.6)
Female	2	2.3	nc	(nc-nc)	Female	246	246.2	99.9	(87.8-113.2)
<u>Lung and Bronchus</u>									
Male	21	31.4	66.8	(41.4-102.2)					
Female	25	35.0	71.5	(46.2-105.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.3	97.7	(53.4-164.0)	Male	20	9.1	218.8	(133.6-337.9)
Female	6	5.6	108.0	(39.4-235.1)	Female	12	7.6	156.9	(81.0-274.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.6	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	6	2.5	244.0	(89.1-531.1)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.1	98.9	(42.6-194.9)
Female	54	60.9	88.6	(66.6-115.7)	Female	6	7.6	79.4	(29.0-172.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	235.3	(75.8-549.2)	Male	4	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	12	15.1	79.6	(41.1-139.1)	<u>Ovary</u>				
Female	9	16.4	54.8	(25.0-104.0)	Female	2	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	8	5.3	151.0	(65.0-297.6)
Female	4	1.1	nc	(nc-nc)	Female	9	5.9	153.2	(69.9-290.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	44	40.9	107.6	(78.2-144.5)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.3	nc	(nc-nc)
Male	10	8.1	123.8	(59.3-227.6)	Female	1	2.3	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.7	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.5	169.1	(61.7-368.0)
<u>Leukemia</u>					Female	12	11.5	104.5	(53.9-182.5)
Male	9	5.7	157.5	(71.9-299.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.5	nc	(nc-nc)	Female	16	13.1	122.4	(69.9-198.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.0	nc	(nc-nc)	Male	198	178.8	110.8	(95.9-127.3)
Female	1	1.8	nc	(nc-nc)	Female	205	205.2	99.9	(86.7-114.5)
<u>Lung and Bronchus</u>									
Male	29	24.7	117.6	(78.7-168.9)					
Female	28	28.1	99.7	(66.2-144.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	12.1	124.0	(69.4-204.6)	Male	9	8.2	110.0	(50.2-208.8)
Female	5	3.9	129.0	(41.6-301.0)	Female	5	6.1	82.2	(26.5-191.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	47	51.6	91.1	(67.0-121.2)	Female	5	5.7	87.3	(28.1-203.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	6	6.6	91.5	(33.4-199.1)
<u>Colon / Rectum</u>					Female	2	2.6	nc	(nc-nc)
Male	9	13.3	67.9	(31.0-128.9)	<u>Ovary</u>				
Female	11	11.4	96.3	(48.0-172.2)	Female	3	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	38	41.6	91.4	(64.7-125.4)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.0	nc	(nc-nc)
Male	5	7.8	64.1	(20.7-149.7)	Female	1	1.6	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.5	142.4	(45.9-332.4)
<u>Leukemia</u>					Female	18	9.8	184.1	(109.1-291.0)
Male	3	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.3	nc	(nc-nc)	Female	13	12.0	108.1	(57.5-184.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.8	104.4	(33.6-243.5)	Male	147	165.2	89.0	(75.2-104.6)
Female	3	1.4	nc	(nc-nc)	Female	170	162.4	104.7	(89.5-121.7)
<u>Lung and Bronchus</u>									
Male	15	22.0	68.1	(38.1-112.4)					
Female	20	21.1	95.0	(58.0-146.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.3	75.2	(30.1-154.9)	Male	5	5.9	84.6	(27.3-197.3)
Female	6	2.5	238.4	(87.1-518.9)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.3	113.2	(41.4-246.5)
Female	31	30.4	102.0	(69.3-144.8)	Female	5	3.5	140.9	(45.4-328.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.6	nc	(nc-nc)
Male	7	9.4	74.6	(29.9-153.8)	<u>Ovary</u>				
Female	6	7.3	81.8	(29.9-178.0)	Female	3	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	28.7	97.7	(64.9-141.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.2	nc	(nc-nc)
Male	2	5.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.9	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	2	6.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.2	nc	(nc-nc)	Male	85	119.1	71.4	(57.0-88.3)
Female	1	0.9	nc	(nc-nc)	Female	87	99.3	87.6	(70.2-108.1)
<u>Lung and Bronchus</u>									
Male	6	16.5	36.3	(13.2-79.0)					
Female	13	13.5	96.5	(51.3-165.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	1.7	292.5	(94.3-682.6)
Female	12	14.3	83.8	(43.3-146.4)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	1	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	10.8	101.4	(50.5-181.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.0	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	48	40.5	118.5	(87.4-157.2)
Female	1	0.4	nc	(nc-nc)	Female	42	47.5	88.5	(63.8-119.6)
<u>Lung and Bronchus</u>									
Male	8	5.3	151.2	(65.1-298.0)					
Female	4	6.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	51.0	100.1	(74.5-131.6)	Male	6	35.9	16.7	(6.1-36.4)
Female	16	21.1	75.9	(43.4-123.3)	Female	9	34.3	26.2	(12.0-49.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	12.8	70.3	(32.1-133.4)	Male	13	11.2	116.2	(61.8-198.7)
Female	7	12.0	58.5	(23.5-120.6)	Female	23	10.2	226.5	(143.5-339.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	25	32.3	77.4	(50.1-114.3)
Female	190	268.5	70.8	(61.1-81.6)	Female	33	31.1	106.3	(73.1-149.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	10.0	170.8	(99.4-273.5)	Male	25	28.2	88.6	(57.3-130.8)
<u>Colon / Rectum</u>					Female	9	14.0	64.1	(29.3-121.7)
Male	63	58.4	108.0	(83.0-138.1)	<u>Ovary</u>				
Female	42	63.9	65.7	(47.3-88.8)	Female	13	22.9	56.8	(30.2-97.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	13.8	50.8	(20.4-104.8)	Male	17	19.7	86.2	(50.2-138.0)
Female	7	4.2	166.6	(66.7-343.2)	Female	13	22.1	58.9	(31.4-100.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.9	nc	(nc-nc)	Male	198	165.9	119.4	(103.3-137.2)
Female	10	5.5	183.1	(87.7-336.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	12.6	126.8	(72.4-205.9)
Male	26	34.0	76.4	(49.9-111.9)	Female	14	9.0	155.9	(85.2-261.6)
Female	29	20.7	139.8	(93.6-200.7)	<u>Testis</u>				
<u>Larynx</u>					Male	11	11.9	92.3	(46.0-165.1)
Male	12	8.0	149.2	(77.0-260.6)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	14	17.6	79.6	(43.5-133.6)
<u>Leukemia</u>					Female	65	58.7	110.7	(85.4-141.1)
Male	21	24.2	86.7	(53.7-132.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	19.5	107.5	(66.5-164.3)	Female	48	58.9	81.5	(60.1-108.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	38	19.8	191.7	(135.6-263.1)	Male	710	712.2	99.7	(92.5-107.3)
Female	16	7.4	215.6	(123.2-350.2)	Female	740	875.4	84.5	(78.6-90.9)
<u>Lung and Bronchus</u>									
Male	93	90.8	102.4	(82.7-125.5)					
Female	101	110.7	91.2	(74.3-110.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	8.9	179.9	(102.8-292.2)	Male	4	5.3	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	5	3.9	129.8	(41.8-303.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	30	31.8	94.3	(63.6-134.6)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	9	8.6	104.2	(47.5-197.8)	<u>Ovary</u>				
Female	11	8.1	135.5	(67.5-242.4)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	24.1	78.9	(47.5-123.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	6	4.5	133.4	(48.7-290.4)	Female	5	1.2	429.7	(138.5-1002.7)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.3	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.3	nc	(nc-nc)	Female	7	7.4	94.3	(37.8-194.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.8	nc	(nc-nc)	Male	105	104.4	100.5	(82.2-121.7)
Female	1	1.0	nc	(nc-nc)	Female	110	107.7	102.1	(83.9-123.1)
<u>Lung and Bronchus</u>									
Male	17	15.2	111.5	(64.9-178.6)					
Female	24	16.0	149.8	(95.9-222.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.5	95.8	(49.4-167.3)	Male	11	8.3	133.3	(66.5-238.6)
Female	4	5.1	nc	(nc-nc)	Female	12	6.8	176.5	(91.1-308.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	7.3	nc	(nc-nc)
Female	39	56.5	69.0	(49.1-94.3)	Female	4	6.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	10	6.4	156.5	(74.9-287.8)
<u>Colon / Rectum</u>					Female	3	3.0	nc	(nc-nc)
Male	7	13.3	52.6	(21.1-108.4)	<u>Ovary</u>				
Female	11	14.0	78.7	(39.2-140.8)	Female	6	4.9	122.4	(44.7-266.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.3	179.2	(65.4-390.1)	Male	1	4.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	6	5.1	117.4	(42.9-255.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	37	40.7	90.8	(64.0-125.2)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	6	7.6	78.8	(28.8-171.5)	Female	0	1.9	nc	(nc-nc)
Female	6	4.6	131.2	(47.9-285.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	6	3.3	180.1	(65.8-392.1)
<u>Leukemia</u>					Female	4	9.7	nc	(nc-nc)
Male	12	5.1	235.3	(121.4-411.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.9	154.2	(56.3-335.6)	Female	12	13.0	92.5	(47.7-161.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.9	nc	(nc-nc)	Male	141	166.1	84.9	(71.5-100.1)
Female	2	1.7	nc	(nc-nc)	Female	158	187.7	84.2	(71.5-98.3)
<u>Lung and Bronchus</u>									
Male	10	22.6	44.3	(21.2-81.4)					
Female	21	27.7	75.9	(47.0-116.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.8	129.3	(70.6-217.0)	Male	7	5.9	119.4	(47.8-246.1)
Female	2	4.3	nc	(nc-nc)	Female	8	4.6	174.4	(75.1-343.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	116.5	(42.5-253.6)
Female	35	36.4	96.1	(66.9-133.7)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	3.7	136.6	(44.0-318.7)
<u>Colon / Rectum</u>					Female	2	2.2	nc	(nc-nc)
Male	14	10.0	140.6	(76.8-235.9)	<u>Ovary</u>				
Female	17	11.9	143.3	(83.4-229.5)	Female	5	3.3	152.0	(49.0-354.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	4.7	107.5	(34.6-250.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	25.2	95.4	(61.1-141.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	5	4.6	109.5	(35.3-255.6)	Female	0	1.7	nc	(nc-nc)
Female	5	3.1	159.1	(51.3-371.4)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.7	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.1	nc	(nc-nc)	Female	5	8.2	61.2	(19.7-142.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	108	114.8	94.1	(77.2-113.6)
Female	2	1.3	nc	(nc-nc)	Female	127	133.8	94.9	(79.1-112.9)
<u>Lung and Bronchus</u>									
Male	11	17.2	64.0	(31.9-114.4)					
Female	16	21.0	76.3	(43.6-123.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	63	47.2	133.3	(102.5-170.6)	Male	22	29.7	74.0	(46.4-112.1)
Female	27	15.7	171.7	(113.1-249.9)	Female	19	22.7	83.9	(50.5-131.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.5	70.2	(25.6-152.8)	Male	10	9.5	105.7	(50.6-194.3)
Female	9	7.3	122.7	(56.0-232.9)	Female	4	7.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	21	26.3	79.8	(49.4-122.0)
Female	169	179.3	94.3	(80.6-109.6)	Female	24	21.8	109.9	(70.4-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	6.1	114.8	(46.0-236.5)	Male	23	21.2	108.5	(68.7-162.8)
<u>Colon / Rectum</u>					Female	12	9.7	123.9	(64.0-216.5)
Male	44	49.0	89.8	(65.2-120.6)	<u>Ovary</u>				
Female	37	46.0	80.4	(56.6-110.8)	Female	29	15.5	187.1	(125.3-268.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	11.4	122.4	(66.9-205.4)	Male	18	17.1	105.1	(62.3-166.2)
Female	2	3.0	nc	(nc-nc)	Female	21	16.4	127.9	(79.1-195.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.3	nc	(nc-nc)	Male	127	130.9	97.0	(80.9-115.4)
Female	3	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	10.9	100.8	(50.3-180.5)
Male	34	25.9	131.1	(90.8-183.2)	Female	1	6.4	nc	(nc-nc)
Female	15	14.3	105.1	(58.8-173.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.3	nc	(nc-nc)
Male	11	6.6	167.0	(83.2-298.8)	<u>Thyroid</u>				
Female	0	2.0	nc	(nc-nc)	Male	13	11.6	112.1	(59.6-191.8)
<u>Leukemia</u>					Female	27	34.8	77.6	(51.1-112.9)
Male	18	18.7	96.4	(57.1-152.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	13.1	107.1	(58.5-179.7)	Female	41	39.8	102.9	(73.9-139.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	15.7	63.6	(30.4-116.9)	Male	579	580.2	99.8	(91.8-108.3)
Female	5	5.3	94.9	(30.6-221.4)	Female	602	599.3	100.5	(92.6-108.8)
<u>Lung and Bronchus</u>									
Male	82	80.7	101.7	(80.9-126.2)					
Female	88	81.8	107.6	(86.3-132.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;